BRPI0515530A - compostos de piperidinilamino-tieno[2,3-d]pirimidina - Google Patents

compostos de piperidinilamino-tieno[2,3-d]pirimidina

Info

Publication number
BRPI0515530A
BRPI0515530A BRPI0515530-4A BRPI0515530A BRPI0515530A BR PI0515530 A BRPI0515530 A BR PI0515530A BR PI0515530 A BRPI0515530 A BR PI0515530A BR PI0515530 A BRPI0515530 A BR PI0515530A
Authority
BR
Brazil
Prior art keywords
compounds
piperidinylamino
novel
hypertension
piperidinylaminothieno
Prior art date
Application number
BRPI0515530-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Dale S Dhanoa
Oren Becker
Silvia Noiman
Sekar Reddy Alla
Rosa E Melendez
Anurag Sharadendu
Dongli Chen
Yael Marantz
Sharon Shacham
Alexander Heifetz
Boaz Inbal
Venkitasamy Kesavan
Shay Bar-Haim
Srinivasa Rao Cheruku
Original Assignee
Epix Delaware Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/947,995 external-priority patent/US20050222175A1/en
Application filed by Epix Delaware Inc filed Critical Epix Delaware Inc
Publication of BRPI0515530A publication Critical patent/BRPI0515530A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BRPI0515530-4A 2004-09-23 2005-09-23 compostos de piperidinilamino-tieno[2,3-d]pirimidina BRPI0515530A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/947,995 US20050222175A1 (en) 2004-03-31 2004-09-23 New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US11/075,565 US7612078B2 (en) 2003-03-31 2005-03-08 Piperidinylamino-thieno[2,3-D] pyrimidine compounds
PCT/US2005/034862 WO2006034511A1 (en) 2004-09-23 2005-09-23 Piperidinylamino-thieno[2,3-d] pyrimidine compounds

Publications (1)

Publication Number Publication Date
BRPI0515530A true BRPI0515530A (pt) 2008-07-29

Family

ID=35528225

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515530-4A BRPI0515530A (pt) 2004-09-23 2005-09-23 compostos de piperidinilamino-tieno[2,3-d]pirimidina

Country Status (21)

Country Link
US (2) US7612078B2 (enExample)
EP (1) EP1797099B1 (enExample)
JP (1) JP2008514643A (enExample)
KR (1) KR20070057970A (enExample)
CN (1) CN101048412A (enExample)
AR (1) AR054982A1 (enExample)
AT (1) ATE477257T1 (enExample)
AU (1) AU2005287898A1 (enExample)
BR (1) BRPI0515530A (enExample)
CA (1) CA2581175A1 (enExample)
DE (1) DE602005022897D1 (enExample)
DK (1) DK1797099T3 (enExample)
HR (1) HRP20100607T1 (enExample)
IL (1) IL182099A0 (enExample)
MX (1) MX2007003026A (enExample)
NO (1) NO20072037L (enExample)
NZ (1) NZ553886A (enExample)
PL (1) PL1797099T3 (enExample)
PT (1) PT1797099E (enExample)
TW (1) TW200628472A (enExample)
WO (1) WO2006034511A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
US7968538B2 (en) * 2005-01-25 2011-06-28 Galenea Corp. Substituted arylamine compounds and methods of treatment
WO2007056214A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc N-alkyl-n-aryl-thienopyrimidin-r-amines and uses thereof
US20070099877A1 (en) * 2005-11-02 2007-05-03 Cytovia, Inc. N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2007056208A2 (en) * 2005-11-02 2007-05-18 Cytovia, Inc. N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7939661B2 (en) * 2006-09-11 2011-05-10 Hoffman-La Roche Inc. Pyridine, quinoline and pyrimidine derivatives
WO2008061966A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh New use of flibanserin
WO2008061968A1 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh Benzimidazolone derivates in the treatment of pulmonary arterial hypertension
CN101820882A (zh) * 2007-09-04 2010-09-01 Epix特拉华公司 用于治疗纤维变性的哌啶基氨基噻吩并[2,3-d]嘧啶类化合物
US8114894B2 (en) * 2008-12-03 2012-02-14 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
US8618116B2 (en) * 2009-08-03 2013-12-31 Daljit Singh Dhanoa Deuterium-enriched pyrimidine compounds and derivatives
EP2595993B1 (en) 2010-07-23 2018-04-18 President and Fellows of Harvard College Tricyclic proteasome activity enhancing compounds
KR101401496B1 (ko) * 2011-05-12 2014-06-11 한국화학연구원 티에노피리미딘 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨 관련 질환의 예방 또는 치료용 약학적 조성물
EP2806875B1 (en) 2012-01-25 2017-07-19 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
CN103467596A (zh) * 2012-06-06 2013-12-25 北京大学 一个治疗肺动脉高压的新靶点
WO2014164543A1 (en) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
CN104592248A (zh) * 2014-12-31 2015-05-06 芜湖杨燕制药有限公司 一种4-氯-6-取代噻吩并[2,3-d]嘧啶化合物的制备方法
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制menin及mll蛋白之交互作用的方法及組合物
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
EP3512857B1 (en) 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Spiro bicyclic inhibitors of menin-mll interaction
CA3033020A1 (en) * 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
CN110248946B (zh) 2016-12-15 2023-05-23 詹森药业有限公司 Menin-MLL相互作用的氮杂环庚烷抑制剂
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
WO2018226976A1 (en) 2017-06-08 2018-12-13 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
EP3684361A4 (en) 2017-09-20 2021-09-08 Kura Oncology, Inc. SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN110075109B (zh) * 2019-03-28 2021-07-27 中国人民解放军军事科学院军事医学研究院 一种促进干细胞因子合成和分泌的化合物及其用途
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN114560843B (zh) * 2022-04-02 2023-04-18 河南维诺生物科技有限公司 一种作为荧光探针的化合物及其合成方法和应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069412A (en) 1958-08-15 1962-12-18 Fmc Corp N-aminoazetidine and preparation thereof
CA933923A (en) 1969-12-19 1973-09-18 Eichenberger Kurt Process for the manufacture of new thiopyranes
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
DE2925175A1 (de) 1979-06-22 1981-01-08 Basf Ag Verfahren zur herstellung von isatosaeureanhydriden
IT1203323B (it) 1987-02-02 1989-02-15 Hoechst Italia Spa Additivo fotoattivatore per composizioni polimeriche costituito dal sale metallico di una cera ossidata
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
US5155115A (en) 1991-03-12 1992-10-13 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5219864A (en) 1991-03-12 1993-06-15 Kyowa Hakko Kogyo Co., Ltd. Thienopyridine derivatives
US5227387A (en) 1991-09-03 1993-07-13 Dowelanco Quinoline nematicidal method
DE4138820A1 (de) 1991-11-26 1993-05-27 Basf Ag Chinolin-3-carbonsaeureamide, deren herstellung und verwendung
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
DE4227747A1 (de) 1992-08-21 1994-02-24 Basf Ag Heteroaromatisch kondensierte Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
US5409948A (en) 1992-11-23 1995-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating cognitive disorders with phenserine
JPH06239858A (ja) 1993-02-16 1994-08-30 Otsuka Pharmaceut Co Ltd 末梢血管拡張剤
GB9306460D0 (en) 1993-03-29 1993-05-19 Smithkline Beecham Plc Novel compounds
TW449600B (en) 1994-04-19 2001-08-11 Takeda Chemical Industries Ltd Condensed-ring thiophene derivatives, their production and use
JP3829879B2 (ja) 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
DE19636769A1 (de) 1996-09-10 1998-03-12 Basf Ag 3-Substituierte Pyrido [4',3':4,5]thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
DE19724980A1 (de) 1997-06-13 1998-12-17 Basf Ag 3-Substituierte 3,4-Dihydro-thieno[2,3-d]pyrimidin-Derivate, ihre Herstellung und Verwendung
JPH11130777A (ja) 1997-08-13 1999-05-18 Takeda Chem Ind Ltd チエノピリジン誘導体、その中間体およびそれらの製造法
ATE404539T1 (de) 1997-10-02 2008-08-15 Eisai R&D Man Co Ltd Kondensierte pyridinderivate
US6103903A (en) 1998-02-26 2000-08-15 Neurogen Corporation 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands
DE19815026A1 (de) 1998-04-03 1999-10-07 Hoechst Schering Agrevo Gmbh Substituierte Piperidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2000064441A2 (en) 1999-04-28 2000-11-02 Respiratorius Ab Compound for use as a medicament for treatment of disorders involving bronchocontraction
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
CA2386163A1 (en) 1999-10-01 2001-04-12 Masanori Tobe Novel quinazoline derivatives
EP1270568A1 (en) 2001-06-19 2003-01-02 Biofrontera Pharmaceuticals AG 1-methyl-4-(3-ethoxy-9h-thioxanthene-ylidene)-piperidine and its use as 5-HT2B and/or H1 antagonist
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
WO2004030629A2 (en) 2002-10-01 2004-04-15 Predix Pharmaceuticals Novel neurokinin antagonists and methods of use thereof
US7153858B2 (en) 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
NZ542236A (en) 2003-03-31 2008-05-30 Predix Pharmaceuticals Holding New piperidinylamino-thieno[2,3-d]pyrimidine compounds
US20050222175A1 (en) 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7119205B2 (en) 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
ES2293287T3 (es) 2003-07-25 2008-03-16 F. Hoffmann-La Roche Ag Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos.
GB0322140D0 (en) 2003-09-22 2003-10-22 Pfizer Ltd Combinations
AU2004290499C1 (en) 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US20060084806A1 (en) 2004-07-21 2006-04-20 Ramasubramanian Sridharan Processes for the preparation of imidazo[1,2-a] pyridine derivatives
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7968538B2 (en) 2005-01-25 2011-06-28 Galenea Corp. Substituted arylamine compounds and methods of treatment
EP1965807A4 (en) 2005-11-23 2010-10-27 Epix Delaware Inc S1P RECEPTOR MODULATING COMPOUNDS AND THEIR USE

Also Published As

Publication number Publication date
WO2006034511A1 (en) 2006-03-30
US20050222176A1 (en) 2005-10-06
IL182099A0 (en) 2007-07-24
PL1797099T3 (pl) 2011-07-29
DK1797099T3 (da) 2010-11-29
CN101048412A (zh) 2007-10-03
MX2007003026A (es) 2007-12-04
NZ553886A (en) 2010-11-26
NO20072037L (no) 2007-06-21
JP2008514643A (ja) 2008-05-08
AU2005287898A1 (en) 2006-03-30
EP1797099B1 (en) 2010-08-11
CA2581175A1 (en) 2006-03-30
KR20070057970A (ko) 2007-06-07
DE602005022897D1 (de) 2010-09-23
US7612078B2 (en) 2009-11-03
AR054982A1 (es) 2007-08-01
ATE477257T1 (de) 2010-08-15
EP1797099A1 (en) 2007-06-20
HRP20100607T1 (hr) 2011-03-31
US20100113485A1 (en) 2010-05-06
PT1797099E (pt) 2010-11-18
TW200628472A (en) 2006-08-16

Similar Documents

Publication Publication Date Title
BRPI0515530A (pt) compostos de piperidinilamino-tieno[2,3-d]pirimidina
CN100519549C (zh) 嘧啶化合物以及含有该化合物的药物组合物
TWI476192B (zh) Jak激酶調節化合物及其使用方法
CA2914168C (en) Pyrido[1,2-a]pyrimidin-4-one derivatives and their use in the treatment of sexual disorders
WO2004089312A3 (en) New piperidinylamino-thieno[2,3-d] pyrimidine compounds
WO2004014850A3 (en) Substituted aminopyrimidines as neurokinin antagonists
Brindisi et al. Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies
WO2004069794A3 (en) New arylpiperazinyl compounds
CL2008003056A1 (es) Compuestos derivados de 3-fenil-imidazo[1,2-a]piridinas; composicion farmaceutica; proceso para su preparacion, util como inhibidores de alk-5 o alk-4 en el tratamiento de enfermedades inflamatorias u obstructivas de las vias respiratorias, cancer, enfermedades musculares, trastornos esqueleticos
MX2010004026A (es) Piperidino-dihidrotienopirimidinas sustituidas.
MA33818B1 (fr) Nouveaux antagonistes du récepteur ccr2 et leurs utilisations
BR9809648A (pt) Derivados de piperazinil-benzil-tetrazol antiinflamatórios e intermediários dos mesmos
NO20084375L (no) Imidazo[1,2-B]pyridaziner, deres fremstilling og deres anvendelse som GABA reseptorligander
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
DOP2012000032A (es) DERIVADOS DE AMIDAS ESPIROCÍCLICAS QUE POSSEN ACTIVIDAD EN LOS RECEPTORES MUSCARINICOS Y RECPETORES ß2
CN101305003A (zh) 用于治疗精神病和神经变性疾病的作为nAChR胆碱能配体的(1-氮杂-双环[3.3.1]壬-4-基)-[5-(1H-吲哚-5-基)-杂芳基)-胺
SV2009002917A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos
WO2007081995A3 (en) Urotensin ii receptor antagonists
DK2619187T3 (en) Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT 1A and 5-HT 2A receptors
KR100932623B1 (ko) 5-ht 수용기에서 활성을 갖는(3,4-다이하이드로-퀴나졸린-2-일)-(2-아릴옥시-에틸)-아민
CN103214473A (zh) 二苯并[b,f][1,4]氧杂氮杂*化合物
JO2629B1 (en) Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
EA200701345A1 (ru) Производные триазолона, тетразолона и имидазолона для применения в качестве антагонистов альфа-2с-адренорецептора
PT2167469E (pt) Derivados de sulfonil-quinoleína
BRPI0414597A (pt) derivados de benzofurano do tipo carbamoìla

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2168 DE 24/07/2012.